CD1d- and MR1-restricted T Cells in Sepsis

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  Szabo, Peter A ^a   Anantha, Ram V ^a   Shaler, Christopher R ^a   McCormick, John K ^a,b   Mansour Haeryfar, S M ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

CD1d; Infection; LPS; MAIT cell; MR1; NKT cell; Sepsis; galactosylceramide

Indexed keywords

CD1D ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIMICROBIAL ACTIVITY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; ESCHERICHIA COLI; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; META ANALYSIS (TOPIC); MUCOSA ASSOCIATED INVARIANT T CELL; NATURAL KILLER T CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SEPSIS; SHIGELLA FLEXNERI; T LYMPHOCYTE; URINARY TRACT INFECTION; VARIANT NATURAL KILLER T CELL;

EID: 84938541271     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00401     Document Type: Review

References (245)

1. Deutschman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity (2014) 40(4):463-75. doi: 10.1016/j.immuni.2014.04.001.
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol (2007) 25:297-336. doi: 10.1146/annurev.immunol.25.022106.141711.
3. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol (2010) 11(3):197-206. doi: 10.1038/ni.1841.
4. Bendelac A. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J Exp Med (1995) 182(6):2091-6.
5. Smiley ST, Kaplan MH, Grusby MJ. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science (1997) 275(5302):977-9.
6. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med (1998) 188(8):1521-8.
7. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol (2006) 177(2):769-75.
8. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Top Microbiol Immunol (2007) 314:113-41.
9. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen specific T cells using fluorescent CD1d tetramers. J Exp Med (2000) 191(11):1895-903.
10. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med (2000) 192(5):741-54.
11. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, Wong CH, et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med (2005) 202(11):1517-26. doi: 10.1084/jem.20051625.
12. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol (2004) 4(3):231-7. doi: 10.1038/nri1309.
13. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, et al. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol (2002) 168(7):3140-4.
14. Park SH, Benlagha K, Lee D, Balish E, Bendelac A. Unaltered phenotype, tissue distribution and function of Valpha14(+) NKT cells in germ-free mice. Eur J Immunol (2000) 30(2):620-5. doi: 10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.0.CO;2-4.
15. D'Andrea A, Goux D, De Lalla C, Koezuka Y, Montagna D, Moretta A, et al. Neonatal invariant Valpha24+ NKT lymphocytes are activated memory cells. Eur J Immunol (2000) 30(6):1544-50.
16. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol (2009) 39(7):1893-901. doi: 10.1002/eji.200939349.
17. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med (2002) 195(5):637-41.
18. Lynch L, Michelet X, Zhang S, Brennan PJ, Moseman A, Lester C, et al. Regulatory iNKT cells lack expression of the transcription factor PLZF and control the homeostasis of T(reg) cells and macrophages in adipose tissue. Nat Immunol (2015) 16(1):85-95. doi: 10.1038/ni.3047.
19. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol (2008) 9(9):1055-64. doi: 10.1038/ni.1641.
20. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A (1998) 95(10):5690-3.
21. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood (2001) 97(7):2067-74.
22. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia (2003) 17(6):1068-77. doi: 10.1038/sj.leu.2402943.
23. Kim HS, Chung DH. IL-9-producing invariant NKT cells protect against DSS-induced colitis in an IL-4-dependent manner. Mucosal Immunol (2013) 6(2):347-57. doi: 10.1038/mi.2012.77.
24. Sag D, Krause P, Hedrick CC, Kronenberg M, Wingender G. IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest (2014) 124(9):3725-40. doi: 10.1172/JCI72308.
25. Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med (2003) 198(7):1069-76. doi: 10.1084/jem.20030630.
26. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, 3rd, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature (2005) 434(7032):525-9. doi: 10.1038/nature03408.
27. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol (2007) 5(6):405-17. doi: 10.1038/nrmicro1657.
28. Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 12(10):966-74. doi: 10.1038/ni.2096.
29. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SM. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med (2011) 17(2):65-77. doi: 10.1016/j.molmed.2010.10.007.
30. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR1311 mediated activation of valpha14 NKT cells by glycosylceramides. Science (1997) 278(5343):1626-9.
31. Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, et al. The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian alpha-linked glycosylceramides. Immunity (2014) 41(4):543-54. doi: 10.1016/j.immuni.2014.08.017.
32. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature (2007) 448(7149):44-9. doi: 10.1038/nature05907.
33. McCarthy C, Shepherd D, Fleire S, Stronge VS, Koch M, Illarionov PA, et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med (2007) 204(5):1131-44. doi: 10.1084/jem.20062342.
34. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 413(6855):531-4. doi: 10.1038/35097097.
35. Haeryfar SM, Lan Z, Leon-Ponte M, Duffy KR, Ge W, Liu W, et al. Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH. Transplantation (2008) 86(3):460-8. doi: 10.1097/TP.0b013e3181806b72.
36. Walker KM, Rytelewski M, Mazzuca DM, Meilleur SA, Mannik LA, Yue D, et al. Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol Cell Biol (2012) 90(6):630-9. doi: 10.1038/icb.2011.78.
37. Anantha RV, Mazzuca DM, Xu SX, Porcelli SA, Fraser DD, Martin CM, et al. T helper type 2-polarized invariant natural killer T cells reduce disease severity in acute intra-abdominal sepsis. Clin Exp Immunol (2014) 178(2):292-309. doi: 10.1111/cei.12404.
38. Forestier C, Takaki T, Molano A, Im JS, Baine I, Jerud ES, et al. Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol (2007) 178(3):1415-25.
39. Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, et al. Glycolipid alpha-C1336 galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 103(30):11252-7. doi: 10.1073/pnas.0604812103.
40. Im JS, Arora P, Bricard G, Molano A, Venkataswamy MM, Baine I, et al. Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 30(6):888-98. doi: 10.1016/j.immuni.2009.03.022.
41. Bai L, Constantinides MG, Thomas SY, Reboulet R, Meng F, Koentgen F, et al. Distinct APCs explain the cytokine bias of alpha-galactosylceramide variants in vivo. J Immunol (2012) 188(7):3053-61. doi: 10.4049/jimmunol.1102414.
42. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 73(3):1890-4. doi: 10.1128/IAI.73.3.1890-1894.2005.
43. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog (2008) 4(12):e1000239. doi: 10.1371/journal.ppat.1000239.
44. Leite-De-Moraes MC, Hameg A, Arnould A, Machavoine F, Koezuka Y, Schneider E, et al. A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement. J Immunol (1999) 163(11):5871-6.
45. Hayworth JL, Mazzuca DM, Maleki Vareki S, Welch I, McCormick JK, Haeryfar SM. CD1d independent activation of mouse and human iNKT cells by bacterial superantigens. Immunol Cell Biol (2012) 90(7):699-709. doi: 10.1038/icb.2011.90.
46. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med (2004) 199(7):947-57. doi: 10.1084/jem.20031389.
47. Rhost S, Sedimbi S, Kadri N, Cardell SL. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand J Immunol (2012) 76(3):246-55. doi: 10.1111/j.1365-3083.2012.02750.x.
48. Girardi E, Maricic I, Wang J, Mac TT, Iyer P, Kumar V, et al. Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nat Immunol (2012) 13(9):851-6. doi: 10.1038/ni.2371.
49. Zhao J, Weng X, Bagchi S, Wang CR. Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response. Proc Natl Acad Sci U S A (2014) 111(7):2674-9. doi: 10.1073/pnas.1323845111.
50. Forestier C, Park SH, Wei D, Benlagha K, Teyton L, Bendelac A. T cell development in mice expressing CD1d directed by a classical MHC class II promoter. J Immunol (2003) 171(8):4096-104.
51. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol (2008) 180(6):3627-35.
52. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 73(1):181-92. doi: 10.1128/IAI.73.1.181-192.2005.
53. Mallevaey T, Zanetta JP, Faveeuw C, Fontaine J, Maes E, Platt F, et al. Activation of invariant NKT cells by the helminth parasite schistosoma mansoni. J Immunol (2006) 176(4):2476-85.
54. Gold MC, Lewinsohn DM. Co-dependents: MR1-restricted MAIT cells and their antimicrobial function. Nat Rev Microbiol (2013) 11(1):14-9. doi: 10.1038/nrmicro2918.
55. Gapin L. Check MAIT. J Immunol (2014) 192(10):4475-80. doi: 10.4049/jimmunol.1400111378 9.
56. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals. J Exp Med (1999) 189(12):1907-21.
57. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med (1993) 178(1):1-16.
58. Seach N, Guerri L, Le Bourhis L, Mburu Y, Cui Y, Bessoles S, et al. Double-positive thymocytes select mucosal-associated invariant T cells. J Immunol (2013) 191(12):6002-9. doi: 10.4049/jimmunol.1301212.
59. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature (2003) 422(6928):164-9. doi: 10.1038/nature01433.
60. Riegert P, Wanner V, Bahram S. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J Immunol (1998) 161(8):4066-77.
61. Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, et al. MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution. Proc Natl Acad Sci U S A (2009) 106(20):8290-5. doi: 10.1073/pnas.0903196106.
62. Tsukamoto K, Deakin JE, Graves JA, Hashimoto K. Exceptionally high conservation of the MHC class I-related gene, MR1, among mammals. Immunogenetics (2013) 65(2):115-24. doi: 10.1007/s00251-012-0666-5.
63. Leeansyah E, Loh L, Nixon DF, Sandberg JK. Acquisition of innate-like microbial reactivity in mucosal tissues during human fetal MAIT-cell development. Nat Commun (2014) 5:3143. doi: 10.1038/ncomms4143.
64. Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM, et al. Human MAIT and CD8alphaalpha cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2012) 119(2):422-33. doi: 10.1182/blood-2011-05-353789.
65. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood (2011) 117(4):1250-9. doi: 10.1182/blood-2010-08-303339.
66. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol (2013) 190(7):3142-52. doi: 10.4049/jimmunol.1203218.
67. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol (2009) 7(3):e54. doi: 10.1371/journal.pbio.1000054.
68. Reantragoon R, Corbett AJ, Sakala IG, Gherardin NA, Furness JB, Chen Z, et al. Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 210(11):2305-20. doi: 10.1084/jem.20130958.
69. Meierovics A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci U S A (2013) 110(33):E3119-28. doi: 10.1073/pnas.1302799110.
70. Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol (2015) 8(2):429-40. doi: 10.1038/mi.2014.81.
71. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, et al. MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog (2013) 9(10):e1003681. doi: 10.1371/journal.ppat.1003681.
72. Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol Immunol (2011) 48(5):769-75. doi: 10.1016/j.molimm.2010.12.002.
73. Chua WJ, Truscott SM, Eickhoff CS, Blazevic A, Hoft DF, Hansen TH. Polyclonal mucosa associated invariant T cells have unique innate functions in bacterial infection. Infect Immun (2012) 80(9):3256-67. doi: 10.1128/IAI.00279-12.
74. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 491(7426):717-23. doi: 10.1038/nature11605.
75. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature (2014) 509(7500):361-5. doi: 10.1038/nature13160.
76. Soudais C, Samassa F, Sarkis M, Le Bourhis L, Bessoles S, Blanot D, et al. In Vitro and In Vivo Analysis of the Gram-Negative Bacteria-Derived Riboflavin Precursor Derivatives Activating Mouse MAIT Cells. J Immunol (2015) 194(10):4641-9. doi: 10.4049/jimmunol.1403224.
77. Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner. Eur J Immunol (2014) 44(1):195-203. doi: 10.1002/eji.201343509.
78. Majno G. The ancient riddle of sigma eta psi iota sigma (sepsis). J Infect Dis (1991) 163(5):937-45.
79. MacFie J. Surgical sepsis. Br J Surg (2013) 100(9):1119-22. doi: 10.1002/bjs.9155_1.
80. Cerra FB. The systemic septic response: multiple systems organ failure. Crit Care Clin (1985) 1(3):591-607.
81. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest (1992) 101(6):1644-55.
82. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 29(7):1303-10.
83. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence (2014) 5(1):4-11. doi: 10.4161/viru.27372.
84. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA (2010) 304(16):1787-94. doi: 10.1001/jama.2010.1553.
85. Shapiro NI, Howell MD, Talmor D, Donnino M, Ngo L, Bates DW. Mortality in Emergency Department Sepsis (MEDS) score predicts 1-year mortality. Crit Care Med (2007) 35(1):192-8. doi: 10.1097/01.CCM.0000251508.12555.3E.
86. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med (2006) 34(1):15-21.
87. Yang Y, Yang KS, Hsann YM, Lim V, Ong BC. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis. J Crit Care (2010) 25(3):398-405. doi: 10.1016/j.jcrc.2009.09.001.
88. Nasa P, Juneja D, Singh O, Dang R, Arora V. Severe sepsis and its impact on outcome in elderly and very elderly patients admitted in intensive care unit. J Intensive Care Med (2012) 27(3):179-83. doi: 10.1177/0885066610397116.
89. Nasa P, Juneja D, Singh O. Severe sepsis and septic shock in the elderly: An overview. World J Crit Care Med (2012) 1(1):23-30. doi: 10.5492/wjccm.v1.i1.23.
90. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving seps is campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.
91. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med (2013) 369(9):840-51. doi: 10.1056/NEJMra1208623.
92. Gu WJ, Wang F, Bakker J, Tang L, Liu JC. The effect of goal-directed therapy on mortality in patients with sepsis-earlier is better: a meta-analysis of randomized controlled trials. Crit Care (2014) 18(5):570. doi: 10.1186/s13054-014-0570-5.
93. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis (2008) 8(1):32-43. doi: 10.1016/S1473-3099(07)70265-7.
94. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science (1986) 234(4775):470-4.
95. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1987) 330(6149):662-4. doi: 10.1038/330662a0.
96. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. Evidence for IFN1488 gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J Immunol (1992) 149(5):1666-70.
97. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest (1993) 103(2):565-75.
98. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science (2015) 347(6227):1260-5. doi: 10.1126/science.aaa4268.
99. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis (2013) 13(3):260-8. doi: 10.1016/S1473-3099(13)70001-X.
100. Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care (2011) 15(4):R183. doi: 10.1186/cc10332.
101. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg (2009) 108(6):1841-7. doi: 10.1213/ane.0b013e318195e11d.
102. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg (1977) 186(3):241-50.
103. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One (2014) 9(2):e98819. doi: 10.1371/journal.pone.0098819.
104. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet (1998) 351(9107):950-3. doi: 10.1016/S0140-6736(05)60606-X.
105. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis (2000) 181(1):176-80. doi: 10.1086/315214.
106. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood (1995) 85(5):1341-7.
107. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest (1991) 88(5):1747-54. doi: 10.1172/JCI115493.
108. Lopez-Collazo E, del Fresno C. Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences. Crit Care (2013) 17(6):242. doi: 10.1186/cc13110.
109. Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, et al. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol (2008) 15(12):1851-8. doi: 10.1128/CVI.00184-08.
110. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 306(23):2594-605. doi: 10.1001/jama.2011.1829.
111. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med (2009) 180(7):640-8. doi: 10.1164/rccm.200903-0363OC.
112. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med (2009) 35(4):678-86. doi: 10.1007/s00134-008-1337-8.
113. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med (2007) 204(6):1463-74. doi: 10.1084/jem.20062602.
114. Shrum B, Anantha RV, Xu SX, Donnelly M, Haeryfar SM, McCormick JK, et al. A robust scoring system to evaluate sepsis severity in an animal model. BMC Res Notes (2014) 7:233. doi: 10.1186/1756-0500-7-233.
115. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE, Jr., Hui JJ, Chang KC, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol (2001) 166(11):6952-63.
116. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF, Wagner TH, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol (2002) 168(5):2493-500.
117. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol (2005) 174(6):3765-72.
118. Toti P, De Felice C, Occhini R, Schuerfeld K, Stumpo M, Epistolato MC, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol (2004) 122(5):765-71. doi: 10.1309/RV6E-9BMC-9954-A2WU.
119. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature (1997) 390(6658):350-1. doi: 10.1038/37022.
120. Faivre V, Lukaszewicz AC, Alves A, Charron D, Payen D, Haziot A. Human monocytes differentiate into dendritic cells subsets that induce anergic and regulatory T cells in sepsis. PLoS One (2012) 7(10):e47209. doi: 10.1371/journal.pone.0047209.
121. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol (1999) 162(7):4148-56.
122. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A (1999) 96(25):14541-6.
123. Donovan S, Bearman GM. Use of intravenous immunoglobulin in critically ill patients. Curr Infect Dis Rep (2014) 16(12):447. doi: 10.1007/s11908-014-0447-4.
124. Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis (1999) 28(4):770-7. doi: 10.1086/515184.
125. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, 1567 an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 309(11):1154-62. doi: 10.1001/jama.2013.2194.
126. Rondon E, Venkataraman R. Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels. Crit Care (2005) 9(5):E20. doi: 10.1186/cc3798.
127. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 29(3):503-10.
128. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 25(7):1115-24.
129. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, et al. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother (2000) 44(3):693-6.
130. Bruno JJ, Dee BM, Anderegg BA, Hernandez M, Pravinkumar SE. US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe sepsis and septic shock. J Crit Care (2012) 27(4):351-61. doi: 10.1016/j.jcrc.2011.12.011.
131. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med (1997) 3(6):678-81.
132. Nalos M, Santner-Nanan B, Parnell G, Tang B, McLean AS, Nanan R. Immune effects of interferon gamma in persistent staphylococcal sepsis. Am J Respir Crit Care Med (2012) 185(1):110-2. doi: 10.1164/ajrccm.185.1.110.
133. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med (2011) 37(3):525-32. doi: 10.1007/s00134-010-2088-x.
134. Sprent J, Surh CD. Interleukin 7, maestro of the immune system. Semin Immunol (2012) 24(3):149-50. doi: 10.1016/j.smim.2012.04.011.
135. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 29(3):313-9. doi: 10.1097/01.cji.0000210386.55951.c2.
136. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 119(4):997-1007. doi: 10.1172/JCI38052.
137. Alstadhaug KB, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch HH, et al. Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurol (2014) 71(8):1030-5. doi: 10.1001/jamaneurol.2014.825.
138. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis (2012) 55(2):291-300. doi: 10.1093/cid/cis383.
139. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 205(7):1701-14. doi: 10.1084/jem.20071681.
140. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol (2010) 184(7):3768-79. doi: 10.4049/jimmunol.0903151.
141. Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, et al. Interleukin-1615 7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis (2012) 206(4):606-16. doi: 10.1093/infdis/jis383.
142. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, et al. IL-7 restores lymphocyte functions in septic patients. J Immunol (2012) 189(10):5073-81. doi: 10.4049/jimmunol.1202062.
143. Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP. Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection. J Immunol (2013) 190(5):1991-2000. doi: 10.4049/jimmunol.1202379.
144. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol (2010) 184(3):1401-9. doi: 10.4049/jimmunol.0902307.
145. Chung KP, Chang HT, Lo SC, Chang LY, Lin SY, Cheng A, et al. Severe Lymphopenia is Associated with Elevated Plasma Interleukin-15 Levels and Increased Mortality during Severe Sepsis. Shock (2015). doi: 10.1097/SHK.0000000000000347.
146. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439(7077):682-7. doi: 10.1038/nature04444.
147. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol (2010) 88(2):233-40. doi: 10.1189/jlb.0110037.
148. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care (2010) 14(6):R220. doi: 10.1186/cc9354.
149. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D, Inflammation, et al. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol (2005) 12(1):60-7. doi: 10.1128/CDLI.12.1.60-67.2005.
150. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock (2000) 13(2):110-6.
151. Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP, Tschope C. Protective role of angiopoietin-1 in endotoxic shock. Circulation (2005) 111(1):97-105. doi: 10.1161/01.CIR.0000151287.08202.8E.
152. Wischmeyer PE, Kahana M, Wolfson R, Ren H, Musch MM, Chang EB. Glutamine reduces cytokine release, organ damage, and mortality in a rat model of endotoxemia. Shock (2001) 16(5):398-402.
153. Lang CH, Bagby GJ, Spitzer JJ. Glucose kinetics and body temperature after lethal and nonlethal doses of endotoxin. Am J Physiol (1985) 248(4 Pt 2):R471-8.
154. Taniguchi T, Shibata K, Yamamoto K, Mizukoshi Y, Kobayashi T. Effects of lidocaine administration on hemodynamics and cytokine responses to endotoxemia in rabbits. Crit Care Med (2000) 28(3):755-9.
155. Carvalho GL, Wakabayashi G, Shimazu M, Karahashi T, Yoshida M, Yamamoto S, et al. Anti interleukin-8 monoclonal antibody reduces free radical production and improves hemodynamics and survival rate in endotoxic shock in rabbits. Surgery (1997) 122(1):60-8.
156. Nielsen JS, Larsson A, Rix T, Nyboe R, Gjedsted J, Krog J, et al. The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. Intensive Care Med (2007) 33(6):1085-93. doi: 10.1007/s00134-007-0631-1.
157. Jourdain M, Carrette O, Tournoys A, Fourrier F, Mizon C, Mangalaboyi J, et al. Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation. Am J Respir Crit Care Med (1997) 156(6):1825-33. doi: 10.1164/ajrccm.156.6.9611100.
158. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ. Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest (1996) 98(7):1533-8. doi: 10.1172/JCI118945.
159. Haudek SB, Natmessnig BE, Furst W, Bahrami S, Schlag G, Redl H. Lipopolysaccharide dose response in baboons. Shock (2003) 20(5):431-6. doi: 10.1097/01.shk.0000090843.66556.74.
160. Kreimeier U, Brueckner UB, Gerspach S, Veitinger K, Messmer K. A porcine model of hyperdynamic endotoxemia: pattern of respiratory, macrocirculatory, and regional blood flow changes. J Invest Surg (1993) 6(2):143-56.
161. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282(5396):2085-8.
162. Fink MP. Animal models of sepsis. Virulence (2014) 5(1):143-53. doi: 10.4161/viru.26083.
163. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol (2007) 81(1):137-43. doi: 10.1189/jlb.0806542.
164. Fink MP, Morrissey PE, Stein KL, Clement RE, Fiallo V, Gardiner WM. Systemic and regional hemodynamic effects of cyclo-oxygenase and thromboxane synthetase inhibition in normal and hyperdynamic endotoxemic rabbits. Circ Shock (1988) 26(1):41-57.
165. Xu D, Qi L, Guillory D, Cruz N, Berg R, Deitch EA. Mechanisms of endotoxin-induced intestinal injury in a hyperdynamic model of sepsis. J Trauma (1993) 34(5):676-82; discussion 82-3.
166. Breslow MJ, Miller CF, Parker SD, Walman AT, Traystman RJ. Effect of vasopressors on organ blood flow during endotoxin shock in pigs. Am J Physiol (1987) 252(2 Pt 2):H291-300.
167. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov (2005) 4(10):854-65. doi: 10.1038/nrd1854.
168. Billiau A. Gamma-interferon: the match that lights the fire? Immunol Today (1988) 9(2):37-40. doi: 10.1016/0167-5699(88)91256-X.
169. Morris M, Li L. Molecular mechanisms and pathological consequences of endotoxin tolerance and priming. Arch Immunol Ther Exp (Warsz) (2012) 60(1):13-8. doi: 10.1007/s00005-011-0155-9.
170. Macarthur H, Couri DM, Wilken GH, Westfall TC, Lechner AJ, Matuschak GM, et al. Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an Escherichia coli model of septic shock: correlation with preserved circulating catecholamines. Crit Care Med (2003) 31(1):237-45. doi: 10.1097/01.CCM.0000045202.66538.DB.
171. Pass LJ, Schloerb PR, Pearce FJ, Drucker WR. Cardiopulmonary response of the rat to gram negative bacteremia. Am J Physiol (1984) 246(3 Pt 2):H344-50.
172. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 5(3):338-43.
173. Castellheim A, Thorgersen EB, Hellerud BC, Pharo A, Johansen HT, Brosstad F, et al. New biomarkers in an acute model of live Escherichia coli-induced sepsis in pigs. Scand J Immunol (2008) 68(1):75-84. doi: 10.1111/j.1365-3083.2008.02122.x.
174. Kazarian KK, Perdue PW, Lynch W, Dziki A, Nevola J, Lee CH, et al. Porcine peritoneal sepsis: modeling for clinical relevance. Shock (1994) 1(3):201-12.
175. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood (2000) 95(4):1117-23.
176. Carroll GC, Snyder JV. Hyperdynamic severe intravascular sepsis depends on fluid administration in cynomolgus monkey. Am J Physiol (1982) 243(1):R131-41.
177. Cryer HM, Garrison RN, Kaebnick HW, Harris PD, Flint LM. Skeletal microcirculatory responses 1709 to hyperdynamic Escherichia coli sepsis in unanesthetized rats. Arch Surg (1987) 122(1):86-92.
178. Rimmele T, Assadi A, Benatir F, Boselli E, Kaminski C, Arnal F, et al. Validation of a Pseudomonas aeruginosa porcine model of septic shock. J Infect (2006) 53(3):199-205. doi: 10.1016/j.jinf.2005.10.023.
179. Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect Immun (1993) 61(7):2741-7.
180. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol (1992) 148(6):1890-7.
181. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, Taiberg L, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis (2006) 193(2):251-8. doi: 10.1086/498909.
182. Matute-Bello G, Frevert CW, Kajikawa O, Skerrett SJ, Goodman RB, Park DR, et al. Septic shock and acute lung injury in rabbits with peritonitis: failure of the neutrophil response to localized infection. Am J Respir Crit Care Med (2001) 163(1):234-43. doi: 10.1164/ajrccm.163.1.9909034.
183. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parrillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest (1986) 78(1):259-70. doi: 10.1172/JCI112559.
184. Goldfarb RD, Glock D, Kumar A, McCarthy RJ, Mei J, Guynn T, et al. A porcine model of peritonitis and bacteremia simulates human septic shock. Shock (1996) 6(6):442-51.
185. Mathiak G, Szewczyk D, Abdullah F, Ovadia P, Feuerstein G, Rabinovici R. An improved clinically relevant sepsis model in the conscious rat. Crit Care Med (2000) 28(6):1947-52.
186. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc (2009) 4(1):31-6. doi: 10.1038/nprot.2008.214.
187. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol (2006) 177(3):1967-74.
188. Hollenberg SM, Dumasius A, Easington C, Colilla SA, Neumann A, Parrillo JE. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med (2001) 164(5):891-5. doi: 10.1164/ajrccm.164.5.2010073.
189. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun (2010) 78(4):1582-92. doi: 10.1128/IAI.01213-09.
190. Lustig MK, Bac VH, Pavlovic D, Maier S, Grundling M, Grisk O, et al. Colon ascendens stent peritonitis-a model of sepsis adopted to the rat: physiological, microcirculatory and laboratory changes. Shock (2007) 28(1):59-64. doi: 10.1097/SHK.0b013e31802e454f.
191. Wang P, Ba ZF, Chaudry IH. Hepatic extraction of indocyanine green is depressed early in sepsis despite increased hepatic blood flow and cardiac output. Arch Surg (1991) 126(2):219-24.
192. Brooks HF, Osabutey CK, Moss RF, Andrews PL, Davies DC. Caecal ligation and puncture in the rat mimics the pathophysiological changes in human sepsis and causes multi-organ dysfunction. Metab Brain Dis (2007) 22(3-4):353-73. doi: 10.1007/s11011-007-9058-1.
193. Muenzer JT, Davis CG, Dunne BS, Unsinger J, Dunne WM, Hotchkiss RS. Pneumonia after cecal ligation and puncture: a clinically relevant "two-hit". model of sepsis. Shock (2006) 26(6):565-70. doi: 10.1097/01.shk.0000235130.82363.ed.
194. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER. Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock (1756 2004) 21(5):415-25.
195. Pene F, Zuber B, Courtine E, Rousseau C, Ouaaz F, Toubiana J, et al. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol (2008) 181(12):8513-20.
196. Benjamim CF, Hogaboam CM, Lukacs NW, Kunkel SL. Septic mice are susceptible to pulmonary aspergillosis. Am J Pathol (2003) 163(6):2605-17. doi: 10.1016/S0002-9440(10)63615-2.
197. Singleton KD, Wischmeyer PE. Distance of cecum ligated influences mortality, tumor necrosis factor-alpha and interleukin-6 expression following cecal ligation and puncture in the rat. Eur Surg Res (2003) 35(6):486-91. doi: 73387.
198. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D. Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun (1999) 67(12):6603-10.
199. Medina E. Murine model of polymicrobial septic peritonitis using cecal ligation and puncture (CLP). Methods Mol Biol (2010) 602:411-5. doi: 10.1007/978-1-60761-058-8_23.
200. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res (1980) 29(2):189-201.
201. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: two distinct animal models for polymicrobial sepsis. Shock (2004) 21(6):505-11.
202. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, et al. Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun (1998) 66(5):2300-9.
203. Zolfaghari PS, Pinto BB, Dyson A, Singer M. The metabolic phenotype of rodent sepsis: cause for concern? Intensive Care Medicine Experimental (2013) 1(1):6. doi: 10.1186/2197-425X-1-6.
204. Chvojka J, Sykora R, Krouzecky A, Radej J, Varnerova V, Karvunidis T, et al. Renal haemodynamic, microcirculatory, metabolic and histopathological responses to peritonitis-induced septic shock in pigs. Crit Care (2008) 12(6):R164. doi: 10.1186/cc7164.
205. Correa TD, Vuda M, Blaser AR, Takala J, Djafarzadeh S, Dunser MW, et al. Effect of treatment delay on disease severity and need for resuscitation in porcine fecal peritonitis. Crit Care Med (2012) 40(10):2841-9. doi: 10.1097/CCM.0b013e31825b916b.
206. Gentile LF, Nacionales DC, Lopez MC, Vanzant E, Cuenca A, Szpila BE, et al. Host responses to sepsis vary in different low-lethality murine models. PLoS One (2014) 9(5):e94404. doi: 10.1371/journal.pone.0094404.
207. Rhee RJ, Carlton S, Lomas JL, Lane C, Brossay L, Cioffi WG, et al. Inhibition of CD1d activation suppresses septic mortality: a role for NK-T cells in septic immune dysfunction. J Surg Res (2003) 115(1):74-81.
208. Teng MW, Yue S, Sharkey J, Exley MA, Smyth MJ. CD1d activation and blockade: a new antitumor strategy. J Immunol (2009) 182(6):3366-71. doi: 10.4049/jimmunol.0802964.
209. Dieude M, Striegl H, Tyznik AJ, Wang J, Behar SM, Piccirillo CA, et al. Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T cells in the normal murine repertoire. J Immunol (2011) 186(8):4771-81. doi: 10.4049/jimmunol.1000921.
210. Hu CK, Venet F, Heffernan DS, Wang YL, Horner B, Huang X, et al. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J Immunol (2009) 182(4):2467-75. doi: 10.4049/jimmunol.0801463.
211. Kattan OM, Kasravi FB, Elford EL, Schell MT, Harris HW. Apolipoprotein E-mediated immune regulation in sepsis. J Immunol (2008) 181(2):1399-408.
212. Van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol (2005) 5(1):31-42. doi: 10.1038/nri1531. y
213. Bedel R, Matsuda JL, Brigl M, White J, Kappler J, Marrack P, et al. Lower TCR repertoire diversity in Traj18-deficient mice. Nat Immunol (2012) 13(8):705-6. doi: 10.1038/ni.2347.
214. Heffernan DS, Monaghan SF, Thakkar RK, Tran ML, Chung CS, Gregory SH, et al. Inflammatory mechanisms in sepsis: elevated invariant natural killer T-cell numbers in mouse and their modulatory effect on macrophage function. Shock (2013) 40(2):122-8. doi: 10.1097/SHK.0b013e31829ca519.
215. Koide N, Morikawa A, Odkhuu E, Haque A, Badamtseren B, Naiki Y, et al. Low susceptibility of NC/Nga mice to the lipopolysaccharide-mediated lethality with D-galactosamine sensitization and the involvement of fewer natural killer T cells. Innate Immun (2012) 18(1):35-43. doi: 10.1177/1753425910390400.
216. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A (1979) 76(11):5939-43.
217. Mannik LA, Chin-Yee I, Sharif S, Van Kaer L, Delovitch TL, Haeryfar SM. Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses. Immunology (2011) 132(3):361-75. doi: 10.1111/j.1365-2567.2010.03369.x.
218. Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, et al. Lethal endotoxic shock using alpha galactosylceramide sensitization as a new experimental model of septic shock. Lab Invest (2006) 86(3):254-61. doi: 10.1038/labinvest.3700388.
219. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 163(9):4647-50.
220. Tumurkhuu G, Koide N, Dagvadorj J, Morikawa A, Hassan F, Islam S, et al. The mechanism of development of acute lung injury in lethal endotoxic shock using alpha-galactosylceramide sensitization. Clin Exp Immunol (2008) 152(1):182-91. doi: 10.1111/j.1365-2249.2008.03603.x.
221. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol (2001) 166(11):6578-84.
222. Yokochi T. A new experimental murine model for lipopolysaccharide-mediated lethal shock with lung injury. Innate Immun (2012) 18(2):364-70. doi: 10.1177/1753425911410236.
223. Dieli F, Sireci G, Russo D, Taniguchi M, Ivanyi J, Fernandez C, et al. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp Med (2000) 192(11):1645-52.
224. Sireci G, La Manna MP, Di Liberto D, Lo Dico M, Taniguchi M, Dieli F, et al. Prophylaxis of lipopolysaccharide-induced shock by alpha-galactosylceramide. J Leukoc Biol (2008) 84(2):550-60. doi: 10.1189/jlb.0707499.
225. Sireci G, La Manna MP, Di Sano C, Di Liberto D, Porcelli SA, Kronenberg M, et al. Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock. J Leukoc Biol (2007) 81(3):607-22. doi: 10.1189/jlb.0506298.
226. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest (2005) 115(9):2572-83. doi: 10.1172/JCI24762.
227. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med (1985) 13(10):818-29.
228. Ly D, Tohn R, Rubin B, Blumenfeld H, Besra GS, Veerapen N, et al. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clin Exp Immunol (2010) 160(2):185-98. doi: 10.1111/j.1365-2249.2009.04074.x.
229. Tohn R, Blumenfeld H, Haeryfar SM, Veerapen N, Besra GS, Porcelli SA, et al. Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes. Clin Exp Immunol (2011) 164(1):26-41. doi: 10.1111/j.1851 1365-2249.2011.04323.x.
230. Yu KO, Im JS, Molano A, Dutronc Y, Illarionov PA, Forestier C, et al. Modulation of CD1d restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 102(9):3383-8. doi: 10.1073/pnas.0407488102.
231. Chau TA, McCully ML, Brintnell W, An G, Kasper KJ, Vines ED, et al. Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome. Nat Med (2009) 15(6):641-8. doi: 10.1038/nm.1965.
232. Higashi H, Suzuki Y, Mukaida N, Takahashi N, Miyamoto D, Matsushima K. Intervention in endotoxin shock by sulfatide (I3SO3-GalCer) with a concomitant reduction in tumor necrosis factor alpha production. Infect Immun (1997) 65(4):1223-7.
233. Squadrito F, Bagnato G, Altavilla D, Ferlito M, Campo GM, Squadrito G, et al. Effect of sulfatide on acute lung injury during endotoxemia in rats. Life Sci (1999) 65(24):2541-52.
234. Kwiecinski J, Rhost S, Lofbom L, Blomqvist M, Mansson JE, Cardell SL, et al. Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway. Infect Immun (2013) 81(4):1114-20. doi: 10.1128/IAI.01334-12.
235. Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest (2007) 117(8):2302-12. doi: 10.1172/JCI31602.
236. Arrenberg P, Maricic I, Kumar V. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology (2011) 140(2):646-55. doi: 10.1053/j.gastro.2010.10.003.
237. Grimaldi D, Le Bourhis L, Sauneuf B, Dechartres A, Rousseau C, Ouaaz F, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med (2014) 40(2):192-201. doi: 10.1007/s00134-013-3163-x.
238. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol (2010) 11(8):701-8. doi: 10.1038/ni.1890.
239. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol (2010) 8(6):e1000407. doi: 10.1371/journal.pbio.1000407.
240. Morison R. Remarks on some functions of the omentum. Br Med J (1906) 1(2350):76-8.
241. van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Esposti MA. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol (2003) 77(3):1877-84.
242. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, et al. The majority of CD1d-sulfatide specific T cells in human blood use a semiinvariant Vdelta1 TCR. Eur J Immunol (2012) 42(9):2505-10. doi: 10.1002/eji.201242531.
243. Luoma AM, Castro CD, Mayassi T, Bembinster LA, Bai L, Picard D, et al. Crystal structure of Vdelta1 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human gammadelta T cells. Immunity (2013) 39(6):1032-42. doi: 10.1016/j.immuni.2013.11.001.
244. Maricic I, Girardi E, Zajonc DM, Kumar V. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. J Immunol (2014) 193(9):4580-9. doi: 10.4049/jimmunol.1400699.
245. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol (2007) 179(8):5126-36.